New features of glatiramer acetate for the treatment of remitting multiple sclerosis
https://doi.org/10.21518/2079-701X-2015-10-60-62
Abstract
The article discusses usage of the new dosage of glatiramer acetate (Copaxone®) for the treatment of relapsing-remitting multiple sclerosis. Results of phase II and III clinical trials are presented. Randomized clinical trials GALA and GLACIER demonstrated high efficacy, good safety and tolerability of glatiramer acetate taken in dosage 40mg/ml 3 times per week.
About the Author
N. Y. Lasch
Russian Medical Research University named after N.I. Pirogov
Russian Federation
Russian Federation
References
1. Rovaris M, Gambinin A, GaLLo A et aL. Axonal injury in earLy muLtipLe scLerosis is irreversibLe and independent of the short-term disease evoLution. Neurology, 2005, 65: 1626-1630.
2. Bitch A, Schuchardt J, Bunckowski S et aL: AxonaL injury in muLtipLe scLerosis. CorreLation with demyeLination and infLammation. Brain, 2000, 123: 1174-1183.
3. Гусев Е.И., Завалишин И.А., Бойко А.Н. (ред). Рассеянный склероз. Клиническое руководство. М.: Реал Тайм, 2011, 528 с.
4. Бойко А.Н. Патогенетическое лечение рассеянного склероза и других аутоиммунных заболеваний нервной системы. В кн. «Аутоиммунные заболевания в неврологии». Клиническое руководство под. ред. И.А. Завалишина, М.А. Пирадова, А.Н. Бойко, С.С. Никитина, Н.Н. Спирина и А.В. Переседовой. РООИ «Здоровье человека», М.: 2014, том 1, с. 285-344.
5. Uitdehaag B, Constantinescu C, CorneLisse P, Jeffry D, Kappos L, Li D, Sandberg-WoLLheim M., TrabouLsee A, Verdum E, Rivera V. Impact of exposure to interferon beta-1a on outcomes in patient with reLapsing-remitting muLtipLe scLerosis: expLoratory anaLyses from the PRISMS Long-term foLLow up study. TherAdv Neurol Disord, 2011, 4:1: 3-14.
6. Бойко А.Н., Давыдовская М.В., Демина Т.Л., Лащ Н.Ю., Овчаров В.В., Попова Е.В., Попова Н.Ф., Ромашкин А.В., Бойко О.В., Хачанова Н.В., Шаранова С.Н, Щур С.Г., Гусев Е.И. Эффективность и переносимость глатирамера ацетата (копаксона) при длительном использовании: 10-летний опыт Московского городского центра рассеянного склероза. Ж. неврологии и психиатрии, 2012. 2 РС вып 2: 86-92.
7. Jonson KP, Ford Cc, Lisakk RP, WoLinsky JS. NeuroLogic consequence of deLaying gLatiramer acetat therapy for muLtipLe scLerosis: 8-year data. Acta Neurol Scand, 2005. 111: 42-47.
8. Рекомендации Всероссийского общества неврологов для проведения курса лечения препаратами, изменяющими течение рассеянного склероза. Журн неврол и психиат, 2009. 109:7:2: 129-134.
9. Teiteibaum D, Meshorer A, HirshfeLd T, Arnon R, SeLa M. Suppression of experimentaL aLLergic encephaLomyeLitis by synthetic poLypeptide. Eur. J. Immunol., 1973, 3: 279-286.
10. Arnon R. Does gLatiramer acetate induce neuro-genesis in experimentaL autoimmune encepha-LomyeLitis. J. neurol., 2007, 254 (SuppL.2): 41-46.
11. Comi G, FiLippi M, WoLinsky JS European/ Canadian muLticenter,doubLe-bLind, randomized, pLacebo-controLLed study of the effects of gLati-ramer acetate on magnetic resonance imaging measured disease activity and burden in patient with reLapsingmuLtipLe scLerosis. European/ Canadian GLatiramer Acetate Study Group. Ann Neurol, 2001, 49: 290-297.
12. Ford C, Johnson K, Brooks B et aL. Sustained efficacy and toLerabiLity of gLatiramer acetate in reLapsing-remitting muLtipLe scLerosis patient for over 10 years. Proceeding of19th Annual Meeting of the ECTRIMS, MiLan, ItaLy, 2003. 483.
13. Шмидт Т.Е., Яхно Н.Н. Рассеянный склероз. Руководство для врачей. М.: МЕДпресс-информ. 2010. 272 с.
14. Devonshire V, Lapierre Y et aL. The GLobaL Adherence Project (GAP); a muLticenter observationaL study on adherence to disease-modifying therapies in patients with reLapsing-remitting muLtipLe scLerosis. Eur. J. Neurol., 2011, 18: 69-77.
15. Cohen J, Rovaris M, Goodman A, FiLippi M; the MRI-AC STUDY GROUP:ResuLts of a randomized, doubLe-bLind,paraLLeL-group study assessing safety and efficacy of 40 mg versus 20 mg of gLatiramer acetate jn MRI-measured disease activity in RRMS. Neurology, 2006. 66: 561.
16. Cohen J, Rovaris M, Goodman A et aL. Randomized, doubLe-bLind, paraLLeL-group, dose-comparison study of gLatirame racetate inreLapsing-remitting muLtipLe scLerosis. Multiple Sclerosis, 2006. 12(1): S99.
17. Comi G, Cohen JA, ArnoLd DL et aL. Phase III dose-comparison study of gLatiramer acetate for muLtipLe scLerosis. Ann Neurol, 2011, 69: 75-82.
18. Khan O, Rieckmann P, Boyko A et aL. Three times weekLy gLatiramer acetate in reLapsing- remitting muLtipLe scLerosis. Ann Neurol, 2013, 73: 705-713.
19. WoLinsky JS, Borresen TE, Dietrich Dw et aL. GLACIER: An open-LabeL, randomized, muLticent-er study to assess the safety and toLerabiLity of gLatiramer acetate 40 mg three time weekLy versus 20 mg daiLy in patient with reLapsing-remitting muLtipLe scLerosis. Mult Scl and Rel Disor, 2015, 4: 370-376.
20. Teva PharmaceuticaLs USA Inc. Copaxone (gLati-ramer acetate injection): prescribing information. PhiLadeLphia (PA): Teva PharmaceuticaLs, 2014.
21. Medicines and HeaLthcare Products ReguLatory Agency. Copaxone 40 mg/mL soLution for injection: summary of product characteristics 2015. Accessed 26 Mar 2015.
Review
For citations:
Lasch NY. New features of glatiramer acetate for the treatment of remitting multiple sclerosis. Meditsinskiy sovet = Medical Council. 2015;(10):60-62. (In Russ.) https://doi.org/10.21518/2079-701X-2015-10-60-62
Views:
442
Email this article 